drugset
drugset / Trial / NCT01282970

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes

NCT01282970 ↗

Phase 1 Completed 72 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 135585 XX following multiple dose administration over 14 days

Timeline

Start
2011-02
Primary completion
2011-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 135585 Unknown 5 mg Oral
Subject BI 135585 Unknown 100 mg Oral

Indications

type 2 diabetes mellitus